Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

TransMedics: Funds totaling $29.75 mil. raised in a recent Series C financing led by 3i Group will be used to support expanded clinical trials for TransMedics' Organ Care System. The organ transport system is designed to optimize organ health and increase the number of usable transplant organs by maintaining the tissue in a warm, functioning state outside of the body. The firm anticipates European approval for the system for heart transplants in early 2007 following the completion of its PROTECT trial in the UK. Thanks to the funds raised, TransMedics plans to initiate trials in the U.S. and Europe and to extend its platform for use with additional organs such as the lungs, liver and kidneys...
Advertisement

Related Content

Curon sells patent to gain Nasdaq compliance
Curon sells patent to gain Nasdaq compliance
Amedica spinal implant cleared
Advertisement
UsernamePublicRestriction

Register

MT023334

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel